The US-based solar technology firm, which counts corporates Mitsui, Moserbaer India and Q-Cells among its backers, has raised an additional $30m.
Month: December 2011
HealthCentral finds effective Remedy
Remedy Health Media is acquiring the online health company, which has raised almost $60m from backers including Interactive Corp. and the Carlyle Group.
Puppet Labs strings together backers
The cloud automation software company has taken its funding to nearly $16m after a series C round, with Google, Cisco and VMware joining as investors.
Joseph Jeong joins Applied Ventures
Joseph Jeong has joined Applied Ventures, the corporate venturing fund for US-based nanomanufacturing technology firm Applied Materials. Jeong joined in August, after pursuing an MBA at the University of Chicago Booth School of Business and an internship at venture capital firm ARCH Venture Partners. Prior to his stint at business school, Jeong held a position… Continue reading Joseph Jeong joins Applied Ventures
XCyton thrills Fidelity
Fidelity Growth Partners India, a private equity division of financial services firm Fidelity Investments, has invested Rs20 crores ($3.9m) in India-based medical diagnostics company XCyton, according to a report in Indian venture capital website VCCircle on Monday. XCyton received an undisclosed amount of funding in 2007 from Birthstone Capital, Amvar Ventures and angel investor Kiran… Continue reading XCyton thrills Fidelity
Morgan Solar closes its second round
Canada-based solar power technology company Morgan Solar secured $9.8m in funding on Tuesday from oil and natural gas delivery corporation Enbridge, taking its series B round to an oversubscribed $28.8m. Enbridge joined energy group Iberdrola and plastics manufacturer Nypro is funding the round. The round follows a similarly oversubscribed series A round last year, which… Continue reading Morgan Solar closes its second round
Rib-X goes for the IPO treatment
The pharmaceuticals company, which is backed by investors including corporate venturing funds from GlaxoSmithKline and AstraZeneca, has filed for an initial public offering which could raise up to $80m.